UNSPSC 51182207: Carbetocin

This classification denotes an oxytocic and uterine stimulant with the molecular formula C45H69N11O12S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88TWF8015Y, chemically known as 1-carboxytocin, 1-butanoic acid-2-(o-methyl-l-tyrosine)- but generally known as carbetocin, which bears US NIH Compound Identifier 71715. European Medicines Agency schedules Carbetocin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06125MIG.

UNSPSC 51182207 Carbetocin, a Commodity code, encompasses pharmaceutical procurement by state and local health systems and multistate cooperative purchasing alliances seeking branded and generic pharmaceutical products. State and local governments buy carbetocin and similarly classified pharmaceutical ingredients and finished products primarily through established cooperative purchasing frameworks that aggregate demand across multiple jurisdictions and healthcare facilities. Recent activity shows procurement focused on establishing master agreements with manufacturers and branded-product suppliers rather than spot purchases, with vendors required to maintain relationships with authorized pharmaceutical wholesalers and demonstrate pricing flexibility through flat-fee, net-price, or WAC-minus formats. Issuing bodies include state departments of administration and their procurement offices administering multistate cooperative purchasing alliances, which typically serve state agencies, county health systems, municipal hospitals, and participating local government healthcare facilities across member jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic and branded pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. The solicitation emphasizes price competitiveness (weighted at 75 percent of evaluation), compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and vendor capacity to supply through three authorized wholesalers with chargeback systems in place. Vendors must carry comprehensive insurance, including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability, and agree to a 3 percent administrative fee on all contract purchases. The contract term spans two years for new responders with optional extensions through June 30, 2028 for incumbent amendments. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, and member-specific healthcare needs.